Odyssey Therapeutics (ODTX) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Odyssey Therapeutics (NASDAQ: ODTX) recently:

• 6/3/2026 – Odyssey Therapeutics was upgraded by Zacks Research to “hold”.
• 6/2/2026 – Odyssey Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 6/2/2026 – Odyssey Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 6/2/2026 – Odyssey Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $26.00 price target on the stock.
• 6/2/2026 – Odyssey Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $30.00 price target on the stock.
• 6/2/2026 – Odyssey Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $40.00 price target on the stock.
• 5/16/2026 – Odyssey Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Transactions at Odyssey Therapeutics

In other news, Director Shelley Chu purchased 11,111 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $199,998.00. Following the acquisition, the director directly owned 11,111 shares of the company’s stock, valued at $199,998. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Tpg Gp A, Llc purchased 1,388,889 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $18.00 per share, with a total value of $25,000,002.00. Following the completion of the acquisition, the insider directly owned 3,690,146 shares in the company, valued at $66,422,628. The trade was a 60.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 4,183,777 shares of company stock worth $75,319,986.